

# Pharma Return on Investment

## P3 R&D in Numbers



**EvaluatePharma Vision estimates a return on investment of 3x from the current industry P3 portfolio**

### Return on investment for current P3 new molecular entities



**\$92 billion**

Aggregate R&D spend of products currently in P3

**3x**



**\$277 billion**

Aggregate NPV of total industry P3 portfolio

Analysis using EvaluatePharma Vision shows 3x return on cumulative R&D spend to 2017 for all novel P3 drugs currently in development.

### Benchmarks for an innovative P3 product

#### TIMELINES



**43 months**

Median time to approval from P3 initiation

#### R&D COSTS



**\$159 million**

Average development cost of P3 product

#### SUCCESS RATES



**54%**

Benchmark USA approval rate for P3 products

NOTE: ROI analysis limited to 700+ unique P3 new molecular entities in development as of September 2018.